Merck's market opportunities lie in its broad biopharmaceutical offerings, targeting oncology, vaccines, and more, alongside extensive veterinary solutions. Its tech-driven innovations, strategic ...

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease ...

Ashwini Vaishnaw meets Merck Electronics EVP Katherine Dei Cas; company shows strong interest in expanding its role in India’s semiconductor ecosystem.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...

The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp., IBM Corp. and Merck & ...

Merck & Co., Inc. (NYSE:MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal valued at over $3 billion, aiming to strengthen its drug pipeline. A close ...

Jan 8 (Reuters) - Merck (MRK.N), opens new tab is in talks to buy cancer drug developer Revolution Medicines (RVMD.O), opens new tab in a $28 billion to $32 billion deal, the Financial Times reported ...

NEW YORK/FRANKFURT, Feb 10 (Reuters) - (This Feb. 10 story has been refiled to say 'LOEs (loss of exclusivity),' not 'LOEs (levels of evidence),' in paragraph 13) Sign up here. Merck, in a statement, ...